Abstract Details

Title Novel Exploratory Study To Examine the Effect of Rasagiline on Tissue Injury in the Substantia Nigra Using Multi-Modal 3T Advanced MRI Techniques in Patients with Parkinson's Disease

Topic Movement Disorders

Presentation(s) P02 - (-)

Poster/Presentation
Number 082

Objective

Background BACKGROUND: Non-conventional MRI sequences including proton-MRS, DTI, and MTR allow quantification of tissue injury in the SN in patients with PD. Rasagline, has been shown to exert an anti-apototic effect on neurons that may be beneficial in PD, independent of its MAO-B inhibiting properties. This provides an opportunity to examine tissue injury in the SN of patients with PD as well as examine the effect of therapies that may reduce dopaminergic cell death in the SN in PD.

Design/Methods DESIGN/METHODS: This is a prospective study in which 25 patients with mild to moderate PD, naive to dopaminergic treatment, initiating therapy with rasagiline 1 mg daily were enrolled. All patients underwent 4 brain MRI scans at - month 3, and months 0, 6 and 12. Between month -3 and month 0 (no treatment), patients were on no therapy and started rasagiline 1 mg daily at month 0 for 12 months study period (treatment period).

Results RESULTS: Data from the first 15 patients enrolled in the study showed than the mean NAA/Cr in the SN improved by 14.46% (p=0.019) and 31.98% (p=0.0004) in the 6 and 12 months periods of treatment, respectively, compared to the no treatment period of 3 months. Similar improvements in MTR and DTI were observed during the treatment period compared to no treatment period. SN in healthy controls did not demonstrate significant change over the same period of time. Additional data will be presented.

Conclusions CONCLUSIONS: Proton MRS may be a sensitive marker of dopaminergic neuronal metabolic injury and shows a decline in a short period of time. Rasagiline may have cytoprotective effect in Parkinson's disease as evidenced from in-vivo imaging. Mechanisms to explain these observations warrant further investigation.

Authors/Disclosures
Edwin B. George, MD, PhD, FAAN (Food and Drug Administration) PRESENTER	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Shana S. Krstevska, MD (Henry Ford Health System)	No disclosure on file
Fen Bao	Fen Bao has nothing to disclose.
Veronica Gorden, BA (Wayne State University)	No disclosure on file
Carla E. Santiago-Martinez (Wayne State University)	Ms. Santiago-Martinez has nothing to disclose.
Natalya Shneyder, MD (UF Health Jacksonville)	Dr. Shneyder has nothing to disclose.
Christina Caon, RN, BS (38 North Street)	Ms. Caon has received personal compensation for serving as an employee of EMD Serono.
Omar A. Khan, MD, PhD (Dept of Neuro/Wayne State Univ Sch of Med)	No disclosure on file

��ɫ��

��ɫ��